ctDNA-based molecular residual disease and survival in resectable colorectal cancer.
Nakamura Y., Watanabe J., Akazawa N., Hirata K., Kataoka K., Yokota M., Kato K., Kotaka M., Kagawa Y., Yeh K-H., Mishima S., Yukami H., Ando K., Miyo M., Misumi T., Yamazaki K., Ebi H., Okita K., Hamabe A., Sokuoka H., Kobayashi S., Laliotis G., Aushev VN., Sharma S., Jurdi A., Liu MC., Aleshin A., Rabinowitz M., Bando H., Taniguchi H., Takemasa I., Kato T., Kotani D., Mori M., Yoshino T., Oki E.
The interim analysis of the CIRCULATE-Japan GALAXY observational study demonstrated the association of circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) detection with recurrence risk and benefit from adjuvant chemotherapy (ACT) in resectable colorectal cancer (CRC). This updated analysis with a 23-month median follow-up, including 2,240 patients with stage II-III colon cancer or stage IV CRC, reinforces the prognostic value of ctDNA positivity during the MRD window with significantly inferior disease-free survival (DFS; hazard ratio (HR): 11.99, P